Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Maxim Merchant Capital, a division of Maxim Group LLC, served as sole placement agent for the financing. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. Read more...
January 18, 2017
Hector E, Cairns D, Michael Wall G. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis. Orphanet J Rare Dis. 2022 Jun 16;17(1):231. doi: 10.1186/s13023-022-02367-w. PMID: 35710564.